Is ROOT Stock the Next Big Thing?
Root Holdings (NASDAQ:ROOT) is the parent company of Root Insurance,…
Sell
1
SURI Quote, Financials, Valuation and Earnings
Last price:
$14.08
Seasonality move
:
0.36%
Day range:
$13.69 - $14.92
52-week range:
$13.69 - $27.52
Dividend yield:
23.1%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.5K
Avg. volume:
1.5K
1-year change:
-40.81%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
$14.24 | -- | -- | -- | $0.68 | 23.1% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$15.32 | -- | -- | -- | $0.24 | 1.56% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$53.37 | -- | -- | -- | $0.00 | 0% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$7.29 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$59.05 | -- | -- | -- | $0.03 | 0.07% | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
$25.07 | -- | -- | -- | $1.17 | 4.68% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.492 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.341 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.324 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.240 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.213 | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | 1.418 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- | -- |
Simplify Propel Opportunities ETF vs. Competitors
-
Which has Higher Returns SURI or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About SURI or BBC?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is SURI or BBC More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.44%.
-
Which is a Better Dividend Stock SURI or BBC?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 23.1%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.56% to investors and pays a quarterly dividend of $0.24 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBC?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns SURI or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About SURI or BBP?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is SURI or BBP More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.442%.
-
Which is a Better Dividend Stock SURI or BBP?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 23.1%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBP?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns SURI or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About SURI or GNOM?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is SURI or GNOM More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.533%.
-
Which is a Better Dividend Stock SURI or GNOM?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 23.1%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or GNOM?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns SURI or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About SURI or PBE?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is SURI or PBE More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.713%.
-
Which is a Better Dividend Stock SURI or PBE?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 23.1%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or PBE?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns SURI or SBIO?
ALPS Medical Breakthroughs ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- -
What do Analysts Say About SURI or SBIO?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than ALPS Medical Breakthroughs ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 SBIOALPS Medical Breakthroughs ETF0 0 0 -
Is SURI or SBIO More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.647%.
-
Which is a Better Dividend Stock SURI or SBIO?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 23.1%. ALPS Medical Breakthroughs ETF offers a yield of 4.68% to investors and pays a quarterly dividend of $1.17 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or SBIO?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta a Good Stock to Buy?
Okta (NASDAQ:OKTA) is used by some of the largest firms…
Is Fidelity High Dividend ETF a Good Investment Now?
Fidelity’s High Dividend ETF (FDVV) is a fund that offers…
Stock Ideas
Sell
37
Is AAPL Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
31
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 32x
Alerts
Sell
45
RGC alert for Apr 5
Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.
Sell
25
GDXU alert for Apr 5
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.
Buy
76
SOXS alert for Apr 5
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.
